The U.S. Food & Drug Administration has approved ZEJULA™ (niraparib) for the maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer following a complete or partial response to a platinum-based chemotherapy regimen. ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer.

Read the Tesaro news release

Review the full prescribing information.